A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon
A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
Inclusion Criteria:
Exclusion Criteria:
South Bend, Indiana 46601, United States
New Brunswick, New Jersey 08903-0019, United States
Bogota, Cundinamarca 0000, Colombia
Bogota, Cundinamarca 0000, Colombia
Bogotá, Cundinamarca 0000, Colombia
Kecskemét, 6000, Hungary
Mexico City, Mexico City 14000, Mexico
Wroclaw, 50-368, Poland
Seoul, 120-752, South Korea
Seoul, 137-701, South Korea